Hematology: Coagulation problems

Sandor S. Shapiro, Stephen Spurgeon

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Lupus anticoagulants (LACs) are immunoglobulins that interfere with in vitro phospholipid-dependent coagulation tests. Initially recognized in the context of systemic lupus erythematosus (SLE), LACs are now known to occur frequently in patients with other disorders, as well as in individuals with no apparent underlying disease. It is now recognized that LACs and anti-cardiolipin antibodies (ACAs) are separate entities, but both are members of a diverse group of immunoglobulins that bind to phospholipid-bound proteins including, but not limited to, β2-glycoprotein-I (β2GPI) and prothrombin. LACs and ACAs are both associated with a high risk of arterial and venous thromboembolicevents, although the mechanism of this thrombotic risk is still unknown. In this chapter the term "anti-phospholipid antibody (APL)" is used to denote the presence of a LAC and/or ACA. The chapter discusses the diagnosis of LACs, the possible thrombotic mechanisms associated with APLs, and the treatment of thrombosis in patients with APLs.

Original languageEnglish (US)
Title of host publicationSystemic Lupus Erythematosus: Fourth Edition
PublisherElsevier Inc.
Pages1139-1160
Number of pages22
ISBN (Print)9780124339019
DOIs
StatePublished - May 2004
Externally publishedYes

Fingerprint

Lupus Coagulation Inhibitor
Hematology
Cardiolipins
Anti-Idiotypic Antibodies
Phospholipids
Immunoglobulins
Prothrombin
Systemic Lupus Erythematosus
Glycoproteins
Thrombosis
Proteins

ASJC Scopus subject areas

  • Immunology and Microbiology(all)

Cite this

Shapiro, S. S., & Spurgeon, S. (2004). Hematology: Coagulation problems. In Systemic Lupus Erythematosus: Fourth Edition (pp. 1139-1160). Elsevier Inc.. https://doi.org/10.1016/B978-012433901-9/50045-4

Hematology : Coagulation problems. / Shapiro, Sandor S.; Spurgeon, Stephen.

Systemic Lupus Erythematosus: Fourth Edition. Elsevier Inc., 2004. p. 1139-1160.

Research output: Chapter in Book/Report/Conference proceedingChapter

Shapiro, SS & Spurgeon, S 2004, Hematology: Coagulation problems. in Systemic Lupus Erythematosus: Fourth Edition. Elsevier Inc., pp. 1139-1160. https://doi.org/10.1016/B978-012433901-9/50045-4
Shapiro SS, Spurgeon S. Hematology: Coagulation problems. In Systemic Lupus Erythematosus: Fourth Edition. Elsevier Inc. 2004. p. 1139-1160 https://doi.org/10.1016/B978-012433901-9/50045-4
Shapiro, Sandor S. ; Spurgeon, Stephen. / Hematology : Coagulation problems. Systemic Lupus Erythematosus: Fourth Edition. Elsevier Inc., 2004. pp. 1139-1160
@inbook{f72eca4efdae4f0e8910a061859d4075,
title = "Hematology: Coagulation problems",
abstract = "Lupus anticoagulants (LACs) are immunoglobulins that interfere with in vitro phospholipid-dependent coagulation tests. Initially recognized in the context of systemic lupus erythematosus (SLE), LACs are now known to occur frequently in patients with other disorders, as well as in individuals with no apparent underlying disease. It is now recognized that LACs and anti-cardiolipin antibodies (ACAs) are separate entities, but both are members of a diverse group of immunoglobulins that bind to phospholipid-bound proteins including, but not limited to, β2-glycoprotein-I (β2GPI) and prothrombin. LACs and ACAs are both associated with a high risk of arterial and venous thromboembolicevents, although the mechanism of this thrombotic risk is still unknown. In this chapter the term {"}anti-phospholipid antibody (APL){"} is used to denote the presence of a LAC and/or ACA. The chapter discusses the diagnosis of LACs, the possible thrombotic mechanisms associated with APLs, and the treatment of thrombosis in patients with APLs.",
author = "Shapiro, {Sandor S.} and Stephen Spurgeon",
year = "2004",
month = "5",
doi = "10.1016/B978-012433901-9/50045-4",
language = "English (US)",
isbn = "9780124339019",
pages = "1139--1160",
booktitle = "Systemic Lupus Erythematosus: Fourth Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Hematology

T2 - Coagulation problems

AU - Shapiro, Sandor S.

AU - Spurgeon, Stephen

PY - 2004/5

Y1 - 2004/5

N2 - Lupus anticoagulants (LACs) are immunoglobulins that interfere with in vitro phospholipid-dependent coagulation tests. Initially recognized in the context of systemic lupus erythematosus (SLE), LACs are now known to occur frequently in patients with other disorders, as well as in individuals with no apparent underlying disease. It is now recognized that LACs and anti-cardiolipin antibodies (ACAs) are separate entities, but both are members of a diverse group of immunoglobulins that bind to phospholipid-bound proteins including, but not limited to, β2-glycoprotein-I (β2GPI) and prothrombin. LACs and ACAs are both associated with a high risk of arterial and venous thromboembolicevents, although the mechanism of this thrombotic risk is still unknown. In this chapter the term "anti-phospholipid antibody (APL)" is used to denote the presence of a LAC and/or ACA. The chapter discusses the diagnosis of LACs, the possible thrombotic mechanisms associated with APLs, and the treatment of thrombosis in patients with APLs.

AB - Lupus anticoagulants (LACs) are immunoglobulins that interfere with in vitro phospholipid-dependent coagulation tests. Initially recognized in the context of systemic lupus erythematosus (SLE), LACs are now known to occur frequently in patients with other disorders, as well as in individuals with no apparent underlying disease. It is now recognized that LACs and anti-cardiolipin antibodies (ACAs) are separate entities, but both are members of a diverse group of immunoglobulins that bind to phospholipid-bound proteins including, but not limited to, β2-glycoprotein-I (β2GPI) and prothrombin. LACs and ACAs are both associated with a high risk of arterial and venous thromboembolicevents, although the mechanism of this thrombotic risk is still unknown. In this chapter the term "anti-phospholipid antibody (APL)" is used to denote the presence of a LAC and/or ACA. The chapter discusses the diagnosis of LACs, the possible thrombotic mechanisms associated with APLs, and the treatment of thrombosis in patients with APLs.

UR - http://www.scopus.com/inward/record.url?scp=59849123263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849123263&partnerID=8YFLogxK

U2 - 10.1016/B978-012433901-9/50045-4

DO - 10.1016/B978-012433901-9/50045-4

M3 - Chapter

AN - SCOPUS:59849123263

SN - 9780124339019

SP - 1139

EP - 1160

BT - Systemic Lupus Erythematosus: Fourth Edition

PB - Elsevier Inc.

ER -